Pathogenesis, Diagnosis, Treatment, and Prognosis of CD20-Positive T and NK Cell Lymphoma: A Review

被引:0
作者
Liu, Yang [1 ]
Li, Bo [2 ]
Chen, Xiaomin [1 ]
Xiong, Hao [1 ]
Huang, Chunlan [1 ,3 ]
机构
[1] Southwest Med Univ, Affiliated Hosp, Stem Cell Immun & Regenerat Key Lab Luzhou, Luzhou, Sichuan, Peoples R China
[2] Southwest Med Univ, Affiliated Hosp, Dept Intens Care Unit, Luzhou, Sichuan, Peoples R China
[3] Southwest Med Univ, Affiliated Hosp, Dept Hematol, Luzhou, Peoples R China
关键词
T-cell lymphoma; NK-T-cell lymphoma; CD20; rituximab; clinical research; ABERRANT EXPRESSION; CD20; EXPRESSION; LOW-LEVEL; ANTIGEN; RITUXIMAB; CANCER;
D O I
10.1615/CritRevImmunol.2025051500
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T and NK cell lymphoma with abnormal CD20 expression is a condition that primarily seen in Asians. Due to the variable expression of CD20, it is difficult to generalize its origin, leading to controversial conclusions about the role of CD20. In this review, we provide an overview of CD20 localization and function in three cell types. In NK/Tcell lymphoma (NKTCL), CD20 was discovered to be confined to B cells, presenting a mature active phenotype and having an inert course. However, in T-cell lymphoma (TCL), variable expression of CD20 antigen on T cells and NK cells correlates with tumor transformation and rituximab efficacy. We highlight the fact that CD20 expression is stage-specific and further classify CD20 antigen assignment,which contributes to understanding the variety of outcome and the function of CD20 during various phases of tumor development.
引用
收藏
页码:11 / 18
页数:8
相关论文
共 41 条
[31]   Peripheral T-Cell Lymphoma with Aberrant Expression of CD19, CD20, and CD79a: Case Report and Literature Review [J].
Matnani, Rahul G. ;
Stewart, Rachel L. ;
Pulliam, Joseph ;
Jennings, Chester D. ;
Kesler, Melissa .
CASE REPORTS IN HEMATOLOGY, 2013, 2013
[32]   Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells [J].
Mueller, Tina ;
Uherek, Christoph ;
Maki, Guitta ;
Chow, Kai Uwe ;
Schimpf, Annemarie ;
Klingemann, Hans-Georg ;
Tonn, Torsten ;
Wels, Winfried S. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (03) :411-423
[33]   Transient expression of CD20 antigen (pan B cell marker) in activated lymph node T cells [J].
Murayama, Y ;
Mukai, R ;
Sata, T ;
Matsunaga, S ;
Noguchi, A ;
Yoshikawa, Y .
MICROBIOLOGY AND IMMUNOLOGY, 1996, 40 (06) :467-471
[34]   CD20+ T-cell Lymphoma Clinicopathologic Analysis of 9 Cases and a Review of the Literature [J].
Rahemtullah, Aliyah ;
Longtine, Janina A. ;
Harris, Nancy Lee ;
Dorn, Michelle ;
Zembowicz, Artur ;
Quintanilla-Fend, Leticia ;
Preffer, Frederic I. ;
Ferry, Judith A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (11) :1593-1607
[35]  
Shao S H, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P1021, DOI 10.3760/cma.j.cn112151-20200212-00081
[36]   Peripheral T-Cell Lymphoma With Aberrant Expression of CD30, CD15, and CD20 [J].
Song, Joo Y. ;
Strom, Ted ;
Raffeld, Mark ;
Pittaluga, Stefania ;
Jaffe, Elaine S. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :E789-E791
[37]  
Teshima Kazuaki, 2017, Rinsho Ketsueki, V58, P2227, DOI 10.11406/rinketsu.58.2227
[38]  
Tschetter Amanda J, 2020, JAAD Case Rep, V6, P308, DOI [10.1016/j.jdcr.2020.01.015, 10.1016/j.jdcr.2020.01.015]
[39]   LOW-LEVEL CD20 EXPRESSION ON T-CELL MALIGNANCIES [J].
WARZYNSKI, MJ ;
GRAHAM, DM ;
AXTELL, RA ;
ZAKEM, MH ;
ROTMAN, RK .
CYTOMETRY, 1994, 18 (02) :88-92
[40]   CD20-positive subcutaneous panniculitis-like T-cell lymphoma presenting as polycranial neuropathy: A CARE-compliant case report and literature review [J].
Xu, Jing ;
Li, Jia ;
Sun, Ya-juan ;
Quan, Wei ;
Liu, Li ;
Zhang, Qing-hui ;
Qin, Yi-dan ;
Pei, Xiao-chen ;
Su, Hang ;
Chen, Jia-Jun .
MEDICINE, 2022, 101 (35) :E30233